Heat shock protein 90 inhibitors protect and restore pulmonary endothelial barrier function

Alexander Antonov, Connie Snead, Boris A Gorshkov, Galina N. Antonova, Alexander Dmitriyevich Verin, John D. Catravas

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Heat shock protein 90 (hsp90) inhibitors inactivate and/or degrade various client proteins, including many involved in inflammation. Increased vascular permeability is a hallmark of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). Thus, we tested the hypothesis that hsp90 inhibitors may prevent and/or restore endothelial cell (EC) permeability after injury. Exposure of confluent bovine pulmonary arterial endothelial cell (BPAEC) monolayer to TGF-β1, thrombin, bacterial lipopolysaccharide (LPS), or vascular endothelial growth factor (VEGF) increased BPAEC permeability, as revealed by decreased transendothelial electrical resistance (TER). Treatment of injured endothelium with hsp90 inhibitors completely restored TER of BPAEC. Similarly, preincubation of BPAEC with hsp90 inhibitors prevented the decline in TER induced by the exposure to thrombin, LPS, VEGF, or TGF-β1. In addition, hsp90 inhibitors restored the EC barrier function after PMA or nocodazole-induced hyperpermeability. These effects of the hsp90 inhibitors were associated with the restoration of TGF-β1-or nocodazole-induced decrease in VE-cadherin and β-catenin expression at EC junctions. The protective effect of hsp90 inhibitors on TGF-β1-induced hyperpermeability was critically dependent upon preservation of F-actin cytoskeleton and was associated with the inhibition of agonist-induced myosin light chain (MLC) and myosin phosphatase target subunit 1 (MYPT1) phosphorylation, F-actin stress fibers formation, microtubule disassembly, increase in hsp27 phosphorylation, and association of hsp90 with hsp27, but independent of p38MAPK activity. We conclude that hsp90 inhibitors exert barrier protective effects on BPAEC, at least in part, via inhibition of hsp27-mediated, agonist-induced cytoskeletal rearrangement, and therefore may have useful therapeutic value in ALI, ARDS, and other pulmonary inflammatory disease.

Original languageEnglish (US)
Pages (from-to)551-559
Number of pages9
JournalAmerican journal of respiratory cell and molecular biology
Volume39
Issue number5
DOIs
StatePublished - Nov 1 2008

Fingerprint

HSP90 Heat-Shock Proteins
Endothelial cells
Endothelial Cells
Lung
Acoustic impedance
Electric Impedance
Myosin-Light-Chain Phosphatase
Nocodazole
Phosphorylation
Acute Lung Injury
Adult Respiratory Distress Syndrome
Thrombin
Vascular Endothelial Growth Factor A
Lipopolysaccharides
Actins
Permeability
Catenins
Stress Fibers
Pulmonary diseases
Intercellular Junctions

Keywords

  • 17-AAG
  • Endothelial permeability
  • MYPT1
  • TGF-β1
  • hsp27

ASJC Scopus subject areas

  • Molecular Biology
  • Pulmonary and Respiratory Medicine
  • Clinical Biochemistry
  • Cell Biology

Cite this

Heat shock protein 90 inhibitors protect and restore pulmonary endothelial barrier function. / Antonov, Alexander; Snead, Connie; Gorshkov, Boris A; Antonova, Galina N.; Verin, Alexander Dmitriyevich; Catravas, John D.

In: American journal of respiratory cell and molecular biology, Vol. 39, No. 5, 01.11.2008, p. 551-559.

Research output: Contribution to journalArticle

Antonov, Alexander ; Snead, Connie ; Gorshkov, Boris A ; Antonova, Galina N. ; Verin, Alexander Dmitriyevich ; Catravas, John D. / Heat shock protein 90 inhibitors protect and restore pulmonary endothelial barrier function. In: American journal of respiratory cell and molecular biology. 2008 ; Vol. 39, No. 5. pp. 551-559.
@article{1e37d06163924e738bf054673286e01f,
title = "Heat shock protein 90 inhibitors protect and restore pulmonary endothelial barrier function",
abstract = "Heat shock protein 90 (hsp90) inhibitors inactivate and/or degrade various client proteins, including many involved in inflammation. Increased vascular permeability is a hallmark of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). Thus, we tested the hypothesis that hsp90 inhibitors may prevent and/or restore endothelial cell (EC) permeability after injury. Exposure of confluent bovine pulmonary arterial endothelial cell (BPAEC) monolayer to TGF-β1, thrombin, bacterial lipopolysaccharide (LPS), or vascular endothelial growth factor (VEGF) increased BPAEC permeability, as revealed by decreased transendothelial electrical resistance (TER). Treatment of injured endothelium with hsp90 inhibitors completely restored TER of BPAEC. Similarly, preincubation of BPAEC with hsp90 inhibitors prevented the decline in TER induced by the exposure to thrombin, LPS, VEGF, or TGF-β1. In addition, hsp90 inhibitors restored the EC barrier function after PMA or nocodazole-induced hyperpermeability. These effects of the hsp90 inhibitors were associated with the restoration of TGF-β1-or nocodazole-induced decrease in VE-cadherin and β-catenin expression at EC junctions. The protective effect of hsp90 inhibitors on TGF-β1-induced hyperpermeability was critically dependent upon preservation of F-actin cytoskeleton and was associated with the inhibition of agonist-induced myosin light chain (MLC) and myosin phosphatase target subunit 1 (MYPT1) phosphorylation, F-actin stress fibers formation, microtubule disassembly, increase in hsp27 phosphorylation, and association of hsp90 with hsp27, but independent of p38MAPK activity. We conclude that hsp90 inhibitors exert barrier protective effects on BPAEC, at least in part, via inhibition of hsp27-mediated, agonist-induced cytoskeletal rearrangement, and therefore may have useful therapeutic value in ALI, ARDS, and other pulmonary inflammatory disease.",
keywords = "17-AAG, Endothelial permeability, MYPT1, TGF-β1, hsp27",
author = "Alexander Antonov and Connie Snead and Gorshkov, {Boris A} and Antonova, {Galina N.} and Verin, {Alexander Dmitriyevich} and Catravas, {John D.}",
year = "2008",
month = "11",
day = "1",
doi = "10.1165/rcmb.2007-0324OC",
language = "English (US)",
volume = "39",
pages = "551--559",
journal = "American Journal of Respiratory Cell and Molecular Biology",
issn = "1044-1549",
publisher = "American Thoracic Society",
number = "5",

}

TY - JOUR

T1 - Heat shock protein 90 inhibitors protect and restore pulmonary endothelial barrier function

AU - Antonov, Alexander

AU - Snead, Connie

AU - Gorshkov, Boris A

AU - Antonova, Galina N.

AU - Verin, Alexander Dmitriyevich

AU - Catravas, John D.

PY - 2008/11/1

Y1 - 2008/11/1

N2 - Heat shock protein 90 (hsp90) inhibitors inactivate and/or degrade various client proteins, including many involved in inflammation. Increased vascular permeability is a hallmark of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). Thus, we tested the hypothesis that hsp90 inhibitors may prevent and/or restore endothelial cell (EC) permeability after injury. Exposure of confluent bovine pulmonary arterial endothelial cell (BPAEC) monolayer to TGF-β1, thrombin, bacterial lipopolysaccharide (LPS), or vascular endothelial growth factor (VEGF) increased BPAEC permeability, as revealed by decreased transendothelial electrical resistance (TER). Treatment of injured endothelium with hsp90 inhibitors completely restored TER of BPAEC. Similarly, preincubation of BPAEC with hsp90 inhibitors prevented the decline in TER induced by the exposure to thrombin, LPS, VEGF, or TGF-β1. In addition, hsp90 inhibitors restored the EC barrier function after PMA or nocodazole-induced hyperpermeability. These effects of the hsp90 inhibitors were associated with the restoration of TGF-β1-or nocodazole-induced decrease in VE-cadherin and β-catenin expression at EC junctions. The protective effect of hsp90 inhibitors on TGF-β1-induced hyperpermeability was critically dependent upon preservation of F-actin cytoskeleton and was associated with the inhibition of agonist-induced myosin light chain (MLC) and myosin phosphatase target subunit 1 (MYPT1) phosphorylation, F-actin stress fibers formation, microtubule disassembly, increase in hsp27 phosphorylation, and association of hsp90 with hsp27, but independent of p38MAPK activity. We conclude that hsp90 inhibitors exert barrier protective effects on BPAEC, at least in part, via inhibition of hsp27-mediated, agonist-induced cytoskeletal rearrangement, and therefore may have useful therapeutic value in ALI, ARDS, and other pulmonary inflammatory disease.

AB - Heat shock protein 90 (hsp90) inhibitors inactivate and/or degrade various client proteins, including many involved in inflammation. Increased vascular permeability is a hallmark of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). Thus, we tested the hypothesis that hsp90 inhibitors may prevent and/or restore endothelial cell (EC) permeability after injury. Exposure of confluent bovine pulmonary arterial endothelial cell (BPAEC) monolayer to TGF-β1, thrombin, bacterial lipopolysaccharide (LPS), or vascular endothelial growth factor (VEGF) increased BPAEC permeability, as revealed by decreased transendothelial electrical resistance (TER). Treatment of injured endothelium with hsp90 inhibitors completely restored TER of BPAEC. Similarly, preincubation of BPAEC with hsp90 inhibitors prevented the decline in TER induced by the exposure to thrombin, LPS, VEGF, or TGF-β1. In addition, hsp90 inhibitors restored the EC barrier function after PMA or nocodazole-induced hyperpermeability. These effects of the hsp90 inhibitors were associated with the restoration of TGF-β1-or nocodazole-induced decrease in VE-cadherin and β-catenin expression at EC junctions. The protective effect of hsp90 inhibitors on TGF-β1-induced hyperpermeability was critically dependent upon preservation of F-actin cytoskeleton and was associated with the inhibition of agonist-induced myosin light chain (MLC) and myosin phosphatase target subunit 1 (MYPT1) phosphorylation, F-actin stress fibers formation, microtubule disassembly, increase in hsp27 phosphorylation, and association of hsp90 with hsp27, but independent of p38MAPK activity. We conclude that hsp90 inhibitors exert barrier protective effects on BPAEC, at least in part, via inhibition of hsp27-mediated, agonist-induced cytoskeletal rearrangement, and therefore may have useful therapeutic value in ALI, ARDS, and other pulmonary inflammatory disease.

KW - 17-AAG

KW - Endothelial permeability

KW - MYPT1

KW - TGF-β1

KW - hsp27

UR - http://www.scopus.com/inward/record.url?scp=55249092971&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55249092971&partnerID=8YFLogxK

U2 - 10.1165/rcmb.2007-0324OC

DO - 10.1165/rcmb.2007-0324OC

M3 - Article

VL - 39

SP - 551

EP - 559

JO - American Journal of Respiratory Cell and Molecular Biology

JF - American Journal of Respiratory Cell and Molecular Biology

SN - 1044-1549

IS - 5

ER -